Cure My Disease

Don't miss your cure!

 Log in / Sign up

Home treatment for collapsed lung could spare patients a hospital stay

NCT ID NCT06471608

Symptom relief Sponsor: University Hospital, Strasbourg, France Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares outpatient (home) care to standard hospital care for people having their first large collapsed lung. 386 adults aged 18-50 will be randomly assigned to either go home with a small chest tube and valve or stay in the hospital. The goal is to see if home treatment improves quality of life over 6 months while being safe and effective.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
chest tube drainage with Heimlich valve
What this could lead to
If successful, this could allow many patients with a first-time collapsed lung to be treated at home, avoiding a hospital stay and improving their quality of life.
What could go wrong
This is a relatively early-stage trial with 386 participants. The outpatient approach may not work for everyone, and some patients may still need hospital admission if complications arise.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 386 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Dec 2025

An estimate. Start dates often move.

Expected to finish

Jul 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 50 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients aged 18 to 50 years presenting to the emergency department with a 1st episode of right or left primary spontaneous pneumothorax (PSP) of large abundance diagnosed by chest X-ray or CT scan defined according to British Thoracic Society (BTS) recommendations as a detachment greater than 2 cm over the entire height of the axillary line. * Patient living less than an hour from hospital and able to be accompanied for the first 48 hours * Patient able to understand the aims and risks of the research and to give informed, dated and signed consent * Patient with Internet access and able to complete online questionnaires * Patient affiliated to or benefiting from a social health insurance Exclusion Criteria: * Small pneumothorax (≤ 2cm) * Suffocating pneumothorax defined by the presence of signs of respiratory distress or hemodynamic failure with indication for emergency exsufflation * Patient on emergency oxygen or long-term oxygen therapy * Traumatic pneumothorax * Secondary spontaneous pneumothorax * Bilateral pneumothorax * Associated fluid effusion * Risk-benefit balance unfavorable to outpatient treatment (comorbidities, isolated patient, difficulty understanding monitoring instructions) * Patient living more than one hour from hospital * Patients living alone or unable to be accompanied on discharge for the first 48 hours * Patients under legal protection * Pregnant or breast-feeding women * Patient participating in a therapeutic interventional clinical trial or in a period of exclusion linked to previous participation in a clinical trial

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ambulatory care are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

familial spontaneous pneumothorax pneumothorax

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ambulatory care Chest tube Primary spontaneous pneumothorax Quality of life

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    7 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHRU de Besançon - Hôpital Jean Minjoz

    Besançon, 25030, France

  • CHU de Grenoble - Hôpital Michallon

    La Tronche, 38700, France

  • Hôpital Pellegrin - CHU de Bordeaux

    Bordeaux, 33000, France

  • Hôpital Saint Louis - AP-HP

    Paris, 75475, France

  • Hôpital Universitaire Pitié Salpétrière AP-HP

    Paris, 75651, France

  • Hôpital de la Milétrie - CHU de Poitiers

    Poitiers, 86021, France

  • Hôpitaux Universitaires de Strasbourg

    Strasbourg, 67091, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.